Project Grant R21AI197061
- Federal Project Grant Summary The University of Vermont & State Agricultural College received a $817,730 Project Grant award dated July 9, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research and development of new analytical tools and methodologies to investigate the mechanisms by which Toxoplasma gondii rhoptry effector proteins are delivered into host cells...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Vermont & State Agricultural College a Project Grant of $438,983 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with completion anticipated by June 30, 2027. This research project focuses on characterizing the biological impact of a novel stable nucleocapsid protein dimer formation in SARS-CoV-2, specifically examining...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Vermont & State Agricultural College a $433,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 12, 2025, with completion targeted for July 31, 2027. This biomedical research project focuses on characterizing the endoplasmic reticulum (ER)-specific autophagy response, termed ER-phagy, as a regulatory mechanism...
- Federal Project Grant Award Summary Tufts University School of Medicine received a $453,750 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2027. The grant funds research to investigate mechanisms by which bacteriophages evade cyclic oligonucleotide-based antiviral defense systems in bacteria, with specific focus on how phage proteins antagonize...
- Federal Grant Award Summary Award Details: This $828,820 Project Grant was awarded on June 11, 2025, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University, with a performance completion date of May 31, 2030. Research Products and Services: The award funds a comprehensive research initiative investigating the molecular mechanisms by which Enterococcus faecalis...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a Project Grant totaling $3,178,626 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 26, 2025 through July 31, 2029. This award supports research investigating Yersinia pseudotuberculosis (YPTB) Type 3 Secretion System (T3SS) effector protein activities in M cells during murine infection. The research...
- Federal Project Grant Award Summary Tufts University School of Medicine received a $151,040 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded January 1, 2026, with completion targeted for August 31, 2028. The research project, "Defining the Unique Divisome of Clostridioides difficile," focuses on identifying and characterizing the cell division machinery of C. difficile,...
- Federal Project Grant Award Summary Tufts University School of Medicine received a Project Grant award of $859,278 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 19, 2026, with completion targeted for January 31, 2031. The grant supports research focused on accelerating the discovery of narrow-spectrum antibiotics targeting Borrelia burgdorferi, the causative agent of Lyme...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $151,808 to the University of Colorado-Denver under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 14, 2025, with a completion date of November 30, 2026. This Project Grant funds investigator-initiated research examining the role of the Group B Streptococcus (GBS) Type VII Secretion System (T7SS) in polymicrobial environments. The research addresses the...
- Federal Grant Award Summary The University of Virginia received a $1,201,716 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 6, 2025, with completion scheduled for July 31, 2030. The grant funds research addressing multidrug-resistant (MDR) Acinetobacter baumannii, a critical global health threat due to its resistance to nearly all available antibiotics. The project develops...
The University of Vermont & State Agricultural College received a $449,393 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 20, 2026 through January 31, 2028. This biomedical research project investigates the differential invasive capacity of Providencia alcalifaciens, a bacterium associated with foodborne diarrheal outbreaks, to identify the genetic and molecular basis of pathogenicity. The funded research encompasses two specific aims: (1) comparative genomic and molecular analysis to determine whether nine genes identified in the Type III secretion system (T3SS) cluster drive invasiveness in P. alcalifaciens using in silico, in vitro, and cellular analysis methods, and (2) establishment of an oral-challenge murine model to assess bacterial colonization and host response upon infection with invasive and non-invasive isolates. This project represents the first systematic investigation of P. alcalifaciens virulence determinants and pathogenic mechanisms, with potential to advance understanding of enterobacterial infections and inform strategies for prevention and treatment of bacterial gastroenteritis. The research will be conducted at the University of Vermont's Burlington, Vermont campus, leveraging the institution's established research infrastructure and expertise in infectious disease research supported through the NIH grant portfolio.Federal Project Grant Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $449.4k | 2/19/26 |